Experiences with Caspofungin Plus Posaconazole in Immunocompromised Adults with Invasive Aspergillosis (IA) Refractory to Prior Standard Therapy

Background: Aspergillosis is a lethal infection of immunocompromised patients that respond poorly to antifungal therapy. Caspofungin (CAS) or Posaconazole (POS) as salvage monotherapy for IA have response rates of 45% and 42% respectively. Preliminary results of in vitro studies, animal models and c...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2006-11, Vol.108 (11), p.5279-5279
Main Authors: Dahlke, Joachim, Zabelina, Tatjana, Lellek, Heinrich, Muth, Alexander, Waschke, Olga, Wolschke, Christine, Sobottka, Ingo, Kroeger, Nicolaus, Zander, Axel R.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Aspergillosis is a lethal infection of immunocompromised patients that respond poorly to antifungal therapy. Caspofungin (CAS) or Posaconazole (POS) as salvage monotherapy for IA have response rates of 45% and 42% respectively. Preliminary results of in vitro studies, animal models and clinical studies suggest that combination therapy with azoles and echinocandins may have additive activity against Aspergillus species. Methods: Seven adult patients after unrelated haematopoietic stem cell transplantation, with proven, probable or possible IA (per EORTC/MSG criteria) and refractory to standard antifungal therapy received Caspofungin plus Posaconazole (standard monotherapy dosage). All patients had > 3 days of combination antifungal therapy. Underlying diseases were AML (n=5), Biphenotypic leukaemia (n=1), Mantle cell Lymphoma (n=1). Three patients were neutropenic (ANC
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V108.11.5279.5279